Supportive evidence of the importance of the contribution of the activated complement system includes the decrease in cure rates of PDT-treated tumours following blockage of complement activation by the inhibitor FUT-175 (Korbelik, 2006), or specific inactivation of complement anaphylatoxins C3a and C5a (Cecic et al, 2005). The gene discussed is C3; the disease is neoplasm.